TTK Healthcare Peer Comparison

NSE: TTKHLTCARE | BSE: 507747

₹1,026.80

₹-19.80 (-1.89%)

As on 08-Oct-2026 10:29IST

Market cap

₹1,479 Cr

Revenue (TTM)

₹888 Cr

P/E Ratio

P/B Ratio

1.3

Div. Yield

1 %

Edit

	TTK Healthcare	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Market cap (₹ Cr)	1,479	34,916	26,070	26,993	25,973
Revenue (₹ Cr)	888	3,564	1,936	9,205	1,462
Net Profit (₹ Cr)	73.96	414.00	288.22	-371.81	387.35
Net Margin (%)	7.71	11.23	14.79	-3.93	26.01
RoE (%)	7.00	8.38	29.77	-3.85	25.18
Price to Earnings	20.00	85.37	90.45	--	67.25
Price-To-Book	1.31	6.94	19.42	3.37	15.05

Income Statement (₹ Cr)

	TTK Healthcare	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Operating Revenue	888.41	3,564.00	1,935.80	9,205.28	1,461.80
Total Income	959.42	3,686.00	1,948.58	9,449.59	1,489.25
Total Expenditure	850.18	2,792.00	1,485.56	8,195.15	919.25
EBITDA	38.23	772.00	450.24	1,010.13	542.56
Depreciation	8.71	226.00	50.83	857.51	37.68
EBIT	29.52	546.00	399.41	152.62	504.88
Interest	2.69	217.00	40.84	342.73	3.77
Other Income	71.01	122.00	12.78	244.31	27.45
Exceptional Items	-4.08	12.00	0.00	-216.88	0.00
Profit before Tax	93.77	463.00	371.35	-162.68	528.56
Provision for Tax	19.81	49.00	83.14	209.13	141.21
Profit after Tax	73.96	414.00	288.22	-371.81	387.35

	TTK Healthcare	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Shareholder's Funds	1,114.85	4,940.00	1,288.82	8,162.62	1,653.56
Minority Interest	0.00	-5.00	0.00	0.00	-1.13
Non-Current Liabilities	7.66	1,712.00	202.03	5,044.14	42.40
Current Liabilities	206.24	1,622.00	835.87	4,758.28	230.82
Total Liabilities	1,328.74	8,578.00	2,326.71	17,723.32	1,983.96

	TTK Healthcare	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Non-Current Assets	79.69	5,343.00	519.60	10,211.52	1,026.85
Current Assets	1,217.90	2,606.00	1,681.81	7,191.66	881.27
Total Assets	1,328.74	8,578.00	2,326.71	17,723.32	1,983.96
Total Debt*	21.90	2,125.00	259.37	5,495.48	26.49
Net Current Assets	1,011.67	984.00	845.94	2,433.38	650.46
Contingent Liabilities	16.76	768.26	19.09	95.72	17.25

	TTK Healthcare	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Cash From Operating Activities	-21.15	390.00	205.05	1,652.60	292.17
Cash Flow from Investing Activities	51.58	-241.00	-409.72	-826.03	-265.94
Cash from Financing Activities	-17.56	-54.00	283.07	-38.98	4.10
Net Cash Inflow / Outflow	12.88	95.00	78.39	787.59	30.33

	TTK Healthcare	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
ROCE (%)	7.72	6.79	29.22	1.24	32.42
ROE (%)	7.00	8.38	29.77	-3.85	25.18
ROA (%)	5.67	4.94	24.77	-2.21	21.93
EBIT Margin (%)	3.32	15.32	20.63	1.66	34.54
Net Margin (%)	7.71	11.23	14.79	-3.93	26.01
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	TTK Healthcare	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Revenue Growth (%)	8.34	18.37	46.65	0.78	40.90
EBIT Growth (%)	33.42	252.26	62.13	-70.53	124.50
Net Profit Growth (%)	17.25	377.85	89.49	-1,383.43	104.15
EPS Growth (%)	14.25	1,001.33	78.60	-484.84	42.32
Book Value Growth (%)	4.70	13.47	144.31	0.33	26.03

	TTK Healthcare	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Price / Earnings	19.20	87.62	89.06	-86.26	67.25
Price / Book Value	1.31	6.94	19.42	3.37	15.05
Dividend Yield (%)	0.96	0.00	0.10	0.00	0.08
EV/EBITDA	22.69	47.12	57.71	30.82	47.51
Market Cap (₹ Cr)	1,046.57	19,071.62	12,753.19	18,108.89	20,944.75

	TTK Healthcare	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debt to Equity	0.00	0.31	0.11	0.53	0.02
Short term debt to equity ratio	0.02	0.09	0.05	0.09	0.02
Current Ratio	5.91	1.61	2.01	1.51	3.82
Quick Ratio	5.38	1.06	1.14	0.87	2.82
Interest Coverage	35.86	3.13	10.09	0.53	141.16

	TTK Healthcare	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debtors to sales (%)	12.46	16.50	26.28	23.44	24.80
Asset Turnover	0.68	0.43	1.66	0.55	0.83
Receivable days	41.32	58.75	40.13	78.20	88.98
Inventory Days	44.63	75.82	60.29	93.30	56.04
Payable days	89.62	186.21	232.47	226.14	99.95
Cash Conversion Cycle	-3.67	-51.64	-132.04	-54.64	45.07

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.